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cytokines, an upregulation of adhesion molecules and 
MHC I and II molecules on mono/macrophages, and an 
expansion of inflammatory monocytes. This exaggerated 
inflammatory response is responsible for necrosis and 
organ failure and results in uncontrolled proliferation and 
phagocytic activity of histiocytes [2].
Hypertriglyceridemia (fasting, greater than or equal 
to 265 mg/100 ml) is one of the current diagnostic crite-
ria for HLH [2]. Several studies link hypertriglyceridemia 
to inhibition of lipoprotein lipase (LPL) by tumor necrosis 
factor-α (TNF-α), and TNF-α is a powerful autocrine and 
paracrine regulator of adipose tissue [3]. Indeed, many dif-
ferent sources of intense and prolonged T-lymphocyte/mac-
rophage activation may be associated with dyslipidemia 
(particularly with hypertriglyceridemia) through inap-
propriate release of TNF-a, IFN-g, GM-CSF and respec-
tively, of IL-1/IL-6, leading to adipose tissue lipolysis with 
increased VLDL secretion, decreased VLDL clearance, 
increased hepatic fatty acid synthesis, and suppression of 
fatty acid oxidation with HIV infection being the well-
known paradigm of this mechanism (possibly enhanced by 
some antiretroviral drugs).
In PubMed there are at least 70 papers in which the asso-
ciation leishmaniasis/(hemophagocytic or haemophago-
cytic) is present. Leishmania parasites have been found to 
be the most common protozoan trigger of acquired HLH. 
In a multicenter prospective study conducted to determine 
the frequency of HLH syndrome in children with VL, ten 
children out of 24 (41 %) with VL developed HLH syn-
drome [4]. HLH incidence in European adult population 
is about 1/800,000/year, with a reported prevalence of 
parasitic infections of 2.4 % (53 out of 2197 subjects), and 
of Leishmania spp. of 0.77 % (17 out of 2197) as a trig-
ger. The clinical picture of VL with HLH initially can be 
indistinguishable from HLH of other etiology, potentially 
Dear Sir,
We found very interesting the paper by Lal et al. about 
hypertriglyceridemia as a possible diagnostic marker of 
disease severity in visceral leishmaniasis (VL) [1]. How-
ever, we think that authors should also have considered the 
possible diagnosis of secondary hemophagocytic lympho-
histiocytosis (HLH).
HLH is a potentially fatal hyperinflammatory syndrome 
characterized by histiocyte proliferation and hemophago-
cytosis. HLH may be inherited (primary, familial) and 
occurs generally in infants or may be secondary to any 
severe infection, malignancy or rheumatologic condition 
and occurring in any age. HLH is diagnosed using clinical 
criteria developed by the HLH Study Group of the Histio-
cyte Society (Table 1) [2]. The mechanism behind second-
ary HLH is not well understood, its clinical picture may 
be identical to primary HLH, but there is more variability 
in severity and outcome. HLH is considered due to a defi-
ciency in cytolytic activity resulting in persistent activation 
of lymphocytes and histiocytes. This uncontrolled immune 
response leads to hypersecretion of pro-inflammatory 
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leading to misdiagnoses and inappropriate therapies [5]. 
However, hypergammaglobulinemia in a patient with HLH 
should raise suspicion for VL as potential trigger because 
this is a feature not commonly reported for other forms of 
HLH [5].
We think that HLH should be considered in severe 
cases of VL especially in those cases that do not promptly 
respond to specific treatment, and, on the contrary, the 
diagnosis of VL must be considered in children with HLH 
if they live or have travelled in VL endemic areas. The 
diagnosis of HLH must be pursued using the HLH 2004 
diagnostic criteria (Table 1), while the diagnosis of VL 
must be pursued using appropriate and sensitive methods 
such as PCR testing of bone marrow specimens.
The preferred treatment for VL in the more economi-
cally developed countries is liposomal amphotericin B. 
Alternative medications are drugs containing pentavalent 
antimony, or miltefosine. The therapy of HLH includes 
steroids, cyclosporine A, etoposide, T-lymphocyte directed 
antibodies, and other biologicals; hematopoietic stem cell 
transplantation is the only way to cure hereditary HLH. 
Case reports and small series anecdotally have reported the 
successful use of liposomal amphotericin B or pentavalent 
antimony in VL complicated by HLH.
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Table 1  HLH 2004 diagnostic criteria (modified from ref. 2)
The diagnosis of HLH can be established if one of either 1 or 2 below is fulfilled:
1. A molecular diagnosis consistent with HLH
2. Diagnostic criteria for HLH are fulfilled (five out of the eight criteria below):
 Fever
 Splenomegaly
 Cytopenias (affecting ≥2 lineages in the peripheral blood):
  Hemoglobin <90 g/l (in infants <4 weeks): hemoglobin <100 g/l
  Platelets <100 × 109/l
  Neutrophils <1 × 109/l
 Hypertriglyceridemia and/or hypofibrinogenemia:
  Fasting triglycerides ≥265 mg/dl
  Fibrinogen ≤1.5 g/l
 Hemophagocytosis in bone marrow or spleen or lymph nodes
 Low or absent NK-cell activity
 Ferritin ≥500 μg/l
 Soluble CD25 ≥2400 U/l
Comments:
(1) If hemophagocytic activity is not proven at the time of presentation, further search for hemophagocytic activity is encouraged. If the bone 
marrow specimen is not conclusive, material may be obtained from other organs. Serial marrow aspirates over time may also be helpful
(2)  The following findings may provide strong supportive evidence for the diagnosis: (a) spinal fluid pleocytosis (mononuclear cells) and/or 
elevated spinal fluid protein, (b) histological picture in the liver resembling chronic persistent hepatitis (biopsy)
(3) Other abnormal clinical and laboratory findings consistent with the diagnosis are: cerebromeningeal symptoms, lymph node enlargement, 
jaundice, edema, skin rash. Hepatic enzyme abnormalities, hypoproteinemia, hyponatremia, VLDL ↑, HDL ↓
